Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
21.98
+0.20 (0.92%)
Aug 4, 2025, 4:00 PM - Market closed
ShockWave Medical Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,204,661
Profits / Employee
$424,876
Market Cap
13.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,682 | 478 | 21.69% |
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | 548 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GMAB News
- 19 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 - GlobeNewsWire
- 4 weeks ago - Genmab Announces Changes to its Executive Committee - GlobeNewsWire
- 5 weeks ago - Completion of Share Buy-back Program - GlobeNewsWire
- 6 weeks ago - Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One - Seeking Alpha
- 6 weeks ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 6 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 6 weeks ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 7 weeks ago - Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - Business Wire